

As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to uncertainties, changes in the organizational structure, redefinition of accounting policies, etc., and may cause the actual results to differ from those stated or implied in this material.

AMOREPACIFIC GROUP has adopted the K-IFRS since 2011 Q1. For fair comparison, we have disclosed the 2010 numbers based on same standards.

## 2011 Q1 Earnings Summary

## Sales up 18\% to KRW 810.3bn, OP up 12\% to KRW 164.5bn

Sales and operating profit growth driven by the strong performance of cosmetics subsidiaries AMOREPACIFIC, Etude and Innisfree
[KRWbn, \%YoY]

## Sales

Operating Profit

## Net Profit





## 2011 Q1 Earnings Summary

## Cosmetics Business



Non-Cosmetics Business
[KRWbn, \%YoY]
[Sales]



## 2011 Q1 Earnings by Division <br> Cosmetics

[KRWbn]

|  | AMOREPACIFIC <br> Consolidated |  | Etude |  |
| :--- | :---: | :---: | :---: | :---: |
|  | Q1 '10 | Q1 '11 | Q1 '10 | Q1 '11 |
| Sales | 585.0 | 692.1 | 41.1 | 53.7 |
| GP | 403.9 | 479.6 | 23.0 | 31.9 |
| SG\&A | 270.4 | 331.6 | 18.2 | 24.2 |
| OP | 133.5 | 148.0 | 4.8 | 7.6 |

AMOREPACIFIC Sales $+18 \%$. OP $+11 \%$

- Strong growth across all divisions
- [Growth by Divsion] Luxury cosmetics $+18 \%$, Premium cosmetics $+14 \%$, Overseas $+17 \%$, MC\&S +23\%
- Continued investments to back mid to long term growth

Etude Sales $+31 \%$. OP $+58 \%$

- Achieved strong growth in both the domestic and overseas markets as a result of aggressive marketing efforts
- Domestic customers +46\%, Foreign customers $+35 \%$
- Profitability improved backed by product mix change and profit growth accelerated thanks to the economy of scale


## Innisfree Sales +71\%. OP +38\%

- Strong performance from the new products "eco make-up" and "eco-science"
- Sales surged as a result of increase number of stores and same store sales growth
- GP margin improved due to the product mix change but SG\&A cost increased as a result of aggressive advertisement


## AMOS Professional Sales +17\%. OP +31\%

- Strong growth across all divisions (Permer, Conditioner, etc.)
- M/S increased : Dec '10 21.5\% $\rightarrow$ Mar ' 11 24.4\%
- Profitability improved backed by product mix change


## 2011 Q1 Earnings by Division _ Non-Cosmetics

[KRWbn]

|  | Pacific Pharma. |  | Pacific Glas |  | Pacific Pharma. Sales -27\%. OP Turn to red <br> - Restructuring to a Medical Beauty company |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Q1 '10 | Q1 '11 | Q1 '10 | Q1 '11 |  |
| Sales | 38.4 | 29.5 | 15.7 | 16.7 | - Sales fell and costs increased as a result of the restructuring process such as reorganization and inventory disposal |
| GP | 19.2 | 12.2 | 2.7 | 2.7 | - Profits expected to recover in 2 H |
| SG\&A | 16.0 | 14.2 | 1.1 | 1.1 | Pacific Glas Sales +7\%. OP -7\% |
| OP | 3.1 | -2.0 | 1.6 | 1.5 |  |
|  | Pacific | Package |  |  | Pacific Package |
|  | Q1 '10 | Q1 '11 | Q1 '10 | Q1 '11 | - Stake acquired in May 2010 |
| Sales |  | 11.5 | 0.2 | 0.4 | - Profitability weakened due to the raw material price hike |
| GP | N/A | 1.3 | 0 | 0.1 | Jangwon Industry Sales +134\%. OP Losses continued |
| SG\&A |  | 0.8 | 0.4 | 0.5 | - Sales to affiliates and non-affiliates showed stable growth |
| OP |  | 0.5 | -0.4 | -0.4 |  |

## 2011 Q1 Financial Summary

- Income Statement
- Balance Sheet

| $[\mathrm{KRW}$ | O1 2010 |  | Q1 2011 |  | [KRWbn] | $\frac{2010.12}{K-1 F R S}$ | $\begin{aligned} & 2011,3 \\ & K-1 F R S \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | S-1FRS | \% | K-IFPS | \% |  |  |  |
| Sa | 686 | 100 | 81 | 100.0 | Asset | 3,801.9 | 3,973.4 |
|  |  |  |  |  | Current Asset | 1,262.4 | 1,376.4 |
| Gross Profit | 463.5 | 67.5 | 554.9 | 68.5 | Non-current Asset | 2,539.4 | 2,597.0 |
|  |  |  |  |  | Liability | 761.1 | 855.9 |
| SG\&A Expense | 316.3 | 46.1 | 390.4 | 48.2 | Current Liability | 463.1 | 549.4 |
| Operating Profit | 147.2 | 21.5 | 164.5 | 20.3 | Non-current Liability | 297.9 | 306.5 |
|  |  |  |  |  | Shareholder's Equity | 3,040.8 | 3,117.5 |
| Non-operating <br> Profit/Expense | 4.1 |  | 6.1 |  | Capital | 44.5 | 44.5 |
| Income Before Taxes | 151.3 | 22.1 | 170.6 | 21.1 | Capital Reserve | 680.5 | 680.5 |
|  |  |  |  |  | Capital Adjustment | -134.1 | -134.1 |
| Consolidated <br> Net Profit | 115.4 | 16.8 | 125.5 | 15.5 | Accumulated Other |  |  |
|  |  |  |  |  | Inclusive Gain and Loss | 9 | 1.7 |
|  |  |  |  |  | Retained Earnings | 1,128.7 | 1,164.0 |
|  |  |  |  |  | Non-Controlling interest | 1,315.4 | 1,361.0 |

